Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

MDGL

Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MDGL
DateTimeSourceHeadlineSymbolCompany
15/06/202411:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
15/06/202411:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
15/06/202407:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
15/06/202406:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
14/06/202407:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
13/06/202407:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
12/06/202407:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/06/202408:48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
06/06/202422:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL CongressNASDAQ:MDGLMadrigal Pharmaceuticals Inc
05/06/202422:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
29/05/202422:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL CongressNASDAQ:MDGLMadrigal Pharmaceuticals Inc
24/05/202411:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
08/05/202406:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
08/05/202406:34Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
08/05/202406:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202423:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202421:00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
25/04/202406:00GlobeNewswire Inc.Madrigal Statement on the Passing of Dr. Stephen HarrisonNASDAQ:MDGLMadrigal Pharmaceuticals Inc
23/04/202422:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
17/04/202406:05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
09/04/202422:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
04/04/202407:05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
19/03/202414:58GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
19/03/202407:04GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Proposed Public OfferingNASDAQ:MDGLMadrigal Pharmaceuticals Inc
15/03/202422:30IH Market NewsAdobe Stock Drops Following Below-Estimate Projections, Cardlytics Surges with Unexpected Profit, and More NewsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
15/03/202407:15GlobeNewswire Inc.Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/03/202408:05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
06/03/202400:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver FibrosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
28/02/202423:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MDGL